FRI0224 Rituximab Selectively Reduces Igg4 Levels in Rheumatoid Arthritis Patients

doi 10.1136/annrheumdis-2017-eular.6690
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ Publishing Group Ltd and European League Against Rheumatism

Related search

Rituximab Therapy in Greek Patients With Rheumatoid Arthritis

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2008English

Safety of Rituximab in Rheumatoid Arthritis

Reumatismo
Rheumatology
2011English

Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials

Journal of Rheumatology
RheumatologyAllergyImmunology
2010English

Rituximab Hypersensitivity in IgG4-related Disease: Successful Desensitization in a Patient With IgG4 Rheumatoid Factor

International Journal of Rheumatic Diseases
Rheumatology
2016English

Serum Serotonin Levels and Bone in Rheumatoid Arthritis Patients

Rheumatology International
RheumatologyAllergyImmunology
2017English

Serum Fetuin-A Levels in Patients With Rheumatoid Arthritis

Nauchno-Prakticheskaya Revmatologiya
RheumatologyAllergyImmunology
2019English

Serological Markers Associated With Disease Activity in Patients With Rheumatoid Arthritis Treated With Rituximab

Journal of International Medical Research
BiochemistryMedicineCell Biology
2016English

Factors Correlated With Improvement of Endothelial Dysfunction During Rituximab Therapy in Patients With Rheumatoid Arthritis

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2013English

Clinical and Immunological Effects of the Original and Biosimilar Rituximab in Patients With Rheumatoid Arthritis

Clinical pharmacology and therapy
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy